

CONFIDENTIAL

Genentech
A Member of the Roche Group

NOTIFICATION PURSUANT TO

18 V.S.A. § 4637(b)

Subject: Notification Pursuant to 18 V.S.A. § 4637(b)

To the Office of the Attorney General of Vermont:

Genentech USA, Inc. hereby notifies the Attorney General of Vermont of the following new prescription drug, pursuant to 18 V.S.A. § 4637(b):

Name of New Prescription Drug	NDC Number	Date of Commercial Availability	WAC (Wholesale Acquisition Cost) (As of the Date of Commercial Availability)
Tecentriq - 840 mg (14mL)	50242-0918-01	March 23, 2019	\$6,216.38

Sincerely,



Maria Aquilina
Director, Government Programs
Genentech USA, Inc.